Advertisement

Psychopharmacology

, Volume 83, Issue 1, pp 104–106 | Cite as

Absolute bioavailability of imipramine: Influence of food

  • Darrell R. Abernethyl
  • Marcia Divoll
  • David J. Greenblatt
  • Jerold S. Harmatz
  • Richard I. Shader
Original Investigations

Abstract

Imipramine hydrochloride (IMI) was administered to 12 healthy volunteers on three occasions in random sequence: 12.5 mg IV, 50 mg orally after overnight fast, and 50 mg orally 30 min after eating a standardized breakfast. IMI concentrations were measured by gas-liquid chromatography using nitrogen-phosphorous detection and pharmacokinetic and bioavailability parameters determined by iterative nonlinear least-squares regression analysis. After IV administration, mean kinetic variables were: volume of distribution, 21.0 l/kg; total clearance, 12.8 ml/min per kg, and elimination half-life, 21.2 h. Mean absolute bioavailability of IMI in the fasting state was 43.6%. When IMI was administered immediately after the standardized meal, absolute bioavailability was 44.1%. After oral administration, the time to peak IMI level was not changed by concurrent food ingestion (2.8 vs 3.2 h after dosage), and the peak IMI concentration was no different (35 vs 30 ng/ml). Thus concurrent food ingestion has no effect on IMI absolute bioavailability, peak concentration attained after oral dosing, or the time to peak concentration.

Key words

Imipramine Antidepressants Pharmacokinetics Bioavailability Food interaction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abernethy DR, Greenblatt DJ, Shader RI (1981) Tricyclic antidepressant determination in human plasma by gas-liquid chromatography using nitrogen-phosphorous detection. Pharmacology 23:57–63Google Scholar
  2. Amsterdam J, Brunswick D, Mendels J (1980) The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. Am J Psychiatry 137:653–662Google Scholar
  3. Anonymous (1959) Weights of insured persons in the United States associated with lowest mortality. Stat Bull Metrop Life Insur Co 40:Nov–DecGoogle Scholar
  4. Brinkshulte M, Breyer-Pfaff U (1979) Binding of tricyclic antidepressants and perazine to human plasma. Naunyn-Schmiedeberg's Arch Pharmacol 308:1–7Google Scholar
  5. Brunswick DJ, Mendels J (1977) Reduced levels of tricyclic antidepressants in plasma from vacutainers. Comm Psychopharmacol 1:131–134Google Scholar
  6. Evans GH, Nies AS, Shand DG (1973) The disposition of propranolol III: Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog, and rat. J Pharmacol Exp Ther 186:114–122Google Scholar
  7. Gram LF, Christiansen J (1975) First-pass metabolism of imipramine in man. Clin Pharmacol Ther 17:555–563Google Scholar
  8. Greenblatt DJ, Koch-Weser J (1975) Clinical pharmacokinetics. N Engl J Med 293:702–705, 964–970Google Scholar
  9. Jorgenson OS, Lober M, Christiansen J, Gram LF (1980) Plasma concentration and clinical effect of imipramine treatment of childhood enuresis. Clin Pharmacokinet 5:386–393Google Scholar
  10. Kristensen CB, Gram LF (1982) Equilibrium dialysis for determination of protein binding in imipramine: evaluation of a method. Acta Pharmacol Toxicol 50:130–136Google Scholar
  11. Kuhn R (1958) The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry 115:459–464Google Scholar
  12. Loo JCK, Riegelman S (1970) Assessment of pharmacokinetic constants from post-infusion blood curves obtained after i.v. infusion. J Pharm Sci 59:53–55Google Scholar
  13. Marquardt DW (1963) An algorithm for least-squares estimation of non-linear parameters. J Soc Ind Appl Math 11:431–441Google Scholar
  14. McAllister RG (1982) Clinical pharmacology of slow channel blocking agents. Prog Cardiovasc Dis 25:83–102Google Scholar
  15. Melander A, Danielson K, Schersten B, Wahlin E (1977a) Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther 22:108–112Google Scholar
  16. Melander A, Berlin-Wahlen A, Bodin NO, Danielson K, Gustafsson B, Lindgren S, Westerlund D (1977b) Bioavailability of d-propoxyphene, acetylsalicyclic acid, and phenazone in a combination tablet (Doleron): interindividual variation and influence of food intake. Acta Med Scand 202:119–124Google Scholar
  17. Melander A, Danielson K, Hanson A, Rudell B, Schersten B, Thulin T, Wahlin E (1977c) Enhancement of hydralazine bioavailability by food. Clin Pharmacol Ther 22:104–107Google Scholar
  18. Newton R (1981) The side effect profile of trazodone in comparison to an active control and placebo. J Clin Psychopharmacol 1 (6 Supp 1):895–935Google Scholar
  19. Rawlins MD, Henderson DB, Hijab AR (1977) Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol 11:283–286Google Scholar
  20. Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M (1976) Physiological disposition of verapamil. Cardiovase Res 10: 605–612Google Scholar
  21. Shand DG, Kornhauser DM, Wilkinson GR (1975) Effects of route of administration and blood flow on hepatic drug elimination. J Pharmacol Exp Ther 195:424–432Google Scholar
  22. Sjoqvist F, Bertilsson L, Asberg M (1980) Monitoring tricyclic antidepressants. Ther Drug Monit 2:85–93Google Scholar
  23. Svensson CK, Edwards DJ, Mauriello PM, Barde SH, Foster AC, Middleton E, Lalka D (1983) Effect of food on hepatic blood flow: implications in the food effect phenomenon. Clin Pharmacol Ther 34:316–323Google Scholar
  24. Usanis RA (1972) NLIN-Nonlinear least-squares estimate of parameters (Library Services Document No. LSR-089-1: Research Triangle Park, N.C., Triangle Universities Computation CenterGoogle Scholar
  25. Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications Hamilton, IllGoogle Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • Darrell R. Abernethyl
    • 1
  • Marcia Divoll
    • 1
  • David J. Greenblatt
    • 1
  • Jerold S. Harmatz
    • 1
  • Richard I. Shader
    • 1
  1. 1.Division of Clinical Pharmacology, Departments of Psychiatry and MedicineTufts University School of Medicine, New England Medical Center HospitalBostonUSA

Personalised recommendations